Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.

Allegretti, Andrew S; Zhang, Wenbin; Zhou, Wenjiong; Thurber, Tara K; Rigby, Scott P; Bowman-Stroud, Cynthia; Trescoli, Carlos; Serusclat, Pierre; Freeman, Mason W; Halvorsen, Yuan-Di C

Allegretti, Andrew S; Zhang, Wenbin; Zhou, Wenjiong; Thurber, Tara K; Rigby, Scott P; Bowman-Stroud, Cynthia; Trescoli, Carlos; Serusclat, Pierre; Freeman, Mason W; Halvorsen, Yuan-Di C.

Afiliación

Allegretti AS; Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA. Electronic address: aallegretti@mgh.harvard.edu.
Zhang W; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA; Shanghai JiaYue PharmaTech, Shanghai, China.
Zhou W; Hopkins Consulting LLC, Philadelphia, PA.
Thurber TK; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA.
Rigby SP; Summit Research Group/Unity Health Network, Munroe Falls, OH.
Bowman-Stroud C; Four Rivers Clinical Research, Paducah, KY.
Trescoli C; Hospital Universitario de la Ribera, Valencia, Spain.
Serusclat P; GHM les Portes du Sud, Venissieux, France.
Freeman MW; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA.
Halvorsen YC; Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA.

Am J Kidney Dis ; 74(3): 328-337, 2019 09.

Article en En | MEDLINE | ID: mdl-31101403

Asunto(s)

Diabetes Mellitus Tipo 2/complicaciones; Piranos/uso terapéutico; Insuficiencia Renal Crónica/complicaciones; Insuficiencia Renal Crónica/tratamiento farmacológico; Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico; Anciano; Método Doble Ciego; Femenino; Humanos; Masculino; Persona de Mediana Edad; Piranos/efectos adversos; Índice de Severidad de la Enfermedad; Inhibidores del Cotransportador de Sodio-Glucosa 2/efectos adversos; Resultado del Tratamiento

Palabras clave

SGLT2 inhibitor; Type 2 diabetes; albuminuria; bexagliflozin; chronic kidney disease (CKD); estimated glomerular filtration rate (eGFR); glucose-lowering therapy; hemoglobin A(1c) (HbA(1c)); kidney function; randomized controlled trial (RCT); renal impairment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Piranos / Diabetes Mellitus Tipo 2 / Insuficiencia Renal Crónica / Inhibidores del Cotransportador de Sodio-Glucosa 2 Tipo de estudio: Clinical_trials Idioma: En Revista: Am J Kidney Dis Año: 2019 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google